Author:
Masuda Kenta,Aoki Daisuke
Publisher
Springer Nature Singapore
Reference58 articles.
1. National Comprehensive Cancer Network NCCN Guidelines Version 1.2020: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. In: 2022. https://www.nccn.org/home/member. Accessed 25 Jun 2022.
2. The Japan Society of Gynecologic Oncology. https://jsgo.or.jp/opinion/05.html. Accessed 25 Jun 2022.
3. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–33.
4. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16.
5. Momozawa Y, Sasai R, Usui Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8:871.